ChromaDex (CDXC) Misses Q3 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
ChromaDex Corporation Reports Third Quarter 2021 Financial Results
November 3, 2021 4:02 PM EDTTotal company net sales of $17.3 million for the three months ended September 30, 2021, with Tru Niagen® net sales of $14.8 million, up 24% from the prior year quarter and gross margin of 61.1% for the quarter.
LOS ANGELES--(BUSINESS WIRE)-- ChromaDex Corp. (NASDAQ: CDXC) today announced financial results for the third quarter of 2021.
Third Quarter 2021 and Recent Highlights
Total net sales were $17.3 million, up 22% from the prior year quarter. Tru Niagen® net sales were $14.8 million, a 24% increase from the prior year... More